| Literature DB >> 36260402 |
Jennifer Viberg Johansson1, Heidi Beate Bentzen2, Nisha Shah3, Eik Haraldsdóttir4, Guðbjörg Andrea Jónsdóttir4, Jane Kaye3,5, Deborah Mascalzoni1,6, Jorien Veldwijk1,7.
Abstract
BACKGROUND: Digital technological development in the last 20 years has led to significant growth in digital collection, use, and sharing of health data. To maintain public trust in the digital society and to enable acceptable policy-making in the future, it is important to investigate people's preferences for sharing digital health data.Entities:
Keywords: discrete choice experiment; health data; preferences; secondary use; willingness to share
Year: 2021 PMID: 36260402 PMCID: PMC8406119 DOI: 10.2196/29614
Source DB: PubMed Journal: JMIR Med Inform
Figure 1An example of a discrete choice experiment with one choice situation.
Descriptive statistics of the respondents presented as percentages, mean, or median with statistical testing between the different countries.
| Variates | Sweden (n=481) | Norway (n=465) | United Kingdom (n=477) | Iceland (n=544) | ||||||||
|
| .15 | |||||||||||
|
| Mean (SD) | 50.3 (16.9) | 48.1 (17.2) | 49.6 (15.9) | 48.3 (17.2) |
| ||||||
|
| Median (range) | 53 (18-88) | 50 (18-84) | 49 (18-90) | 47 (19-88) |
| ||||||
| Survey duration, mean (SD) | 15.5 (11.5) | 15.4 (10.2) | 12.8 (7.36) | 20.7 (14.9) | <.001 | |||||||
aANOVA: analysis of variance.
Descriptive statistics of the respondents presented as percentages with Kruskal-Wallis testing between the different countries.
| Variates | Sweden (n=447) | Norway (n=425) | United Kingdom (n=445) | Iceland (n=501) | |||
|
| <.001 | ||||||
|
| High school | 251 (56.2) | 234 (55.1) | 129 (29) | 181 (36.1) |
| |
|
| Primary school | 34 (7.6) | 24 (5.6) | 84 (18.9) | 33 (6.6) |
| |
|
| University | 162 (36.2) | 167 (39.3) | 232 (52.1) | 287 (57.3) |
| |
|
| <.001 | ||||||
|
| Insufficient | 115 (25.7) | 126 (29.6) | 116 (26.1) | 183 (36.5) |
| |
|
| Problematic | 195 (43.6) | 202 (47.5) | 166 (37.3) | 215 (42.9) |
| |
|
| Sufficient | 137 (30.6) | 97 (22.8) | 163 (36.6) | 103 (20.6) |
| |
|
| <.001 | ||||||
|
| Daily | 64 (14.3) | 71 (16.7) | 107 (24) | 87 (17.4) |
| |
|
| Weekly | 52 (11.6) | 44 (10.4) | 51 (11.5) | 69 (13.8) |
| |
|
| Monthly or more seldom | 121 (27.1) | 152 (35.8) | 57 (12.8) | 145 (28.9) |
| |
|
| Never | 176 (39.4) | 109 (25.6) | 212 (47.6) | 144 (28.7) |
| |
|
| I don’t know | 34 (7.6) | 49 (11.5) | 18 (4) | 56 (11.2) |
| |
|
| .04 | ||||||
|
| Yes | 312 (69.8) | 261 (61.4) | 306 (68.8) | 341 (68.1) |
| |
|
| .05 | ||||||
|
| Yes | 365 (81.7) | 328 (77.2) | 330 (74.2) | 395 (78.8) |
| |
Estimates for the multinomial logit model with all countries together.
| Attribute and level | Logit | |||
|
| Estimate (SE) | 95% CI | ||
|
| ||||
|
| A technological company | −0.19 (0.02) | <.001 | −0.22 to −0.16 |
|
| A research project | 0.08 (0.02) | <.001 | 0.05 to 0.11 |
|
| Your health care provider (Refa) | 0.11 (N/Ab) | N/A | N/A |
|
| ||||
|
| A technological company | −0.26 (0.02) | <.001 | −0.31 to −0.22 |
|
| A pharmaceutical company | −0.03 (0.02) | .15 | −0.08 to 0.012 |
|
| A research project | 0.12 (0.02) | <.001 | 0.08 to 0.16 |
|
| A national authority (Ref) | 0.17 (N/A) | N/A | N/A |
|
| ||||
|
| Develop a new product or service | 0.15 (0.02) | <.001 | 0.11 to 0.20 |
|
| Promoting, advertising, or marketing | −0.47 (0.02) | <.001 | −0.52 to −0.42 |
|
| Investigate a policy initiative | 0.11 (0.02) | N/A | 0.07 to 0.15 |
|
| Evaluate the quality (Ref) | 0.21 (N/A) | N/A | N/A |
|
| ||||
|
| Not informed | −0.90 (0.02) | <.001 | −0.95 to −0.85 |
|
| Informed | −0.08 (0.02) | .001 | −0.12 to −0.03 |
|
| Informed and ability to opt out | 0.51 (0.02) | <.001 | 0.46 to 0.55 |
|
| Informed and consent (Ref) | 0.47 (N/A) | N/A | N/A |
|
| ||||
|
| No specific review | −0.52 (0.02) | <.001 | −0.56 to −0.49 |
|
| Review of sharing | 0.25 (0.02) | <.001 | 0.22 to 0.30 |
|
| Review of sharing and use (Ref) | 0.27 (N/A) | N/A | N/A |
| Intercept | 0.51 (0.01) | <.001 | 0.49 to 0.54 | |
aReference category.
bN/A: not applicable.
Estimates for the latent class model, four classes with country as class membership.
| Attribute and level | Latent class | ||||||||
|
| Class 1 | Class 2 | Class 3 | Class 4 | |||||
|
| Estimate (SE) | Estimate (SE) | Estimate (SE) | Estimate (SE) | |||||
|
| |||||||||
|
| A technological company | −0.26a (0.10) | −0.37b (0.04) | −0.36b (0.06) | −0.40b (0.08) | ||||
|
| A research project | 0.14 (0.11) | 0.15b (0.03) | 0.21b (0.05) | 0.16a (0.07) | ||||
|
| Your health care provider (Refc) | 0.13 (N/Ad) | 0.22 (N/A) | 0.15 (N/A) | 0.25 (N/A) | ||||
|
| |||||||||
|
| A technological company | −0.41a (0.16) | −0.53b (0.04) | −0.07 (0.07) | −0.59b (0.09) | ||||
|
| A pharmaceutical company | −0.12 (0.14) | −0.08 (0.04) | −0.08 (0.07) | −0.05 (0.08) | ||||
|
| A research project | 0.17 (0.13) | 0.29b (0.05) | 0.07 (0.07) | 0.23 (0.09) | ||||
|
| A national authority (Ref) | 0.36 (N/A) | 0.32 (N/A) | 0.08 (N/A) | 0.41 (N/A) | ||||
|
| |||||||||
|
| Develop a new product or service | 0.56b (0.16) | 0.33b (0.04) | 0.04 (0.07) | 0.43b (0.09) | ||||
|
| Promoting, advertising, or marketing | −1.06b (0.19) | −0.98b (0.06) | −0.41b (0.09) | −0.76b (0.10) | ||||
|
| Investigate a policy initiative | 0.10 (0.14) | 0.25b (0.04) | 0.05 (0.07) | −0.05b (0.09) | ||||
|
| Evaluate the quality (Ref) | 0.40 (N/A) | 0.40 (N/A) | 0.32 (N/A) | 0.38 (N/A) | ||||
|
| |||||||||
|
| Not informed | −1.47b (0.19) | −0.66b (0.06) | −2.95b (0.12) | −1.36b (0.12) | ||||
|
| Informed | 0.02 (0.18) | −0.04 (0.05) | −0.41b (0.07) | −0.11 (0.09) | ||||
|
| Informed and ability to opt out | 0.82b (0.19) | 0.35b (0.05) | 1.61b (0.10) | 0.84b (0.08) | ||||
|
| Informed and consent (Ref) | 0.65 (N/A) | 0.31 (N/A) | 1.34 (N/A) | 0.51 (N/A) | ||||
|
| |||||||||
|
| No specific review | −0.78b (0.13) | −1.07b (0.05) | −0.58b (0.07) | −0.75b (0.09) | ||||
|
| Review of sharing | 0.43b (0.12) | 0.50b (0.04) | 0.28b (0.06) | 0.46b (0.07) | ||||
|
| Review of sharing and use (Ref) | 0.35 (N/A) | 0.57 (N/A) | 0.30 (N/A) | 0.29 (N/A) | ||||
| Intercept | 3.60b (0.14) | 0.31b (0.04) | 0.84b (0.06) | −2.01b (0.09) | |||||
| AICe | 29,730 (N/A) | N/A | N/A | N/A | |||||
| Log-likelihood | −14,797 (N/A) | N/A | N/A | N/A | |||||
| Average class probability (%) | 27 (N/A) | 32 (N/A) | 23 (N/A) | 18 (N/A) | |||||
|
| |||||||||
|
| Constant | 0.96b (0.17) | 0.73b (0.19) | 0.87b (0.18) | Ref | ||||
|
| Sweden | −0.29 (0.22) | 0.09 (0.23) | −0.91b (0.25) | Ref | ||||
|
| Norway | −1.06b (0.22) | −0.78b (0.24) | −0.50a (0.22) | Ref | ||||
|
| Iceland | −0.76b (0.22) | 0.15 (0.23) | −0.98b (0.24) | Ref | ||||
aSignificance at 5% level.
bSignificance at 1% level.
cRef: Reference category.
dN/A: not applicable.
eAIC: Akaike information criteria.
Figure 2Relative importance score for respondents’ preferences stratified using the four-class model. The reason and having a review process in place were most important for class 2. Being informed was most important for classes 1, 3, and 4.
Figure 3Relative importance score for all respondents’ preferences, stratified by country. Receiving information and having the opportunity to opt out was the most important attribute, on average, followed by review process and the reason for sharing the information.
The acceptance uptake (class adjusted probability) when health information is shared from a health care setting to a technological company.
| Scenarios | Not informed (%) | Informed (%) | Opt-out (%) | Consent (%) | |
|
| |||||
|
| Develop a new product or service | 32 | 49 | 63 | 63 |
|
| Promoting, advertising, or marketing | 18 | 37 | 53 | 60 |
|
| Investigate a policy initiative | 29 | 47 | 61 | 61 |
|
| Evaluate the quality | 32 | 51 | 64 | 64 |
|
| |||||
|
| Develop a new product or service | 45 | 65 | 77 | 76 |
|
| Promoting, advertising, or marketing | 32 | 52 | 65 | 65 |
|
| Investigate a policy initiative | 43 | 63 | 75 | 74 |
|
| Evaluate the quality | 46 | 66 | 77 | 76 |
|
| |||||
|
| Develop a new product or service | 45 | 65 | 77 | 76 |
|
| Promoting, advertising, or marketing | 31 | 53 | 65 | 64 |
|
| Investigate a policy initiative | 43 | 63 | 74 | 73 |
|
| Evaluate the quality | 46 | 66 | 77 | 76 |
Descriptive statistics of the respondents presented as percentages with Chi-square testing between the different countries.
| Variates | Sweden (n=438) | Norway (n=424) | United Kingdom (n=450) | Iceland (n=538) | |||
|
| .79 | ||||||
|
| Female | 219 (50) | 226 (53.3) | 236 (52.4) | 268 (49.8) |
| |
|
| Male | 218 (49.8) | 197 (46.5) | 214 (47.6) | 268 (49.8) |
| |
|
| Other | 1 (0.2) | 1 (0.2) | 0 (0) | 2 (0.4) |
| |
|
| <.001 | ||||||
|
| Good | 296 (67.6) | 285 (67.2) | 335 (74.4) | 445 (82.7) |
| |
|
| <.001 | ||||||
|
| No | 203 (46.3) | 179 (42.2) | 262 (58.2) | 304 (56.5) |
| |